DBV Technologies | DBVT - Operating Profit


DBV Technologies reported $-34.28M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025